MRTNZ

MRTNZ Investment Office · The 360 Vantage

ALNY · NASDAQ-GS

Alnylam Pharmaceuticals, Inc.

Health Care · Biotechnology: Pharmaceutical Preparations

Reference price$288.41As of Jul 28, 2026
Market capitalization$38.51B
52-week range$262.21–$495.55
QQQ portfolio weight0.18%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$380.00+31.8% vs. reference
Average$455.06+57.8% vs. reference
High$550.00+90.7% vs. reference
19 Buy1 Hold0 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportJul 30, 2026Jun 2026
Consensus EPS$1.448 estimates
Expected range$1.00–$1.86Low to high EPS
Dec 2026$7.35Street EPS consensus
Dec 2027$10.32Street EPS consensus
Dec 2028$13.22Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue+65.2% YoY$3.71B$2.25B
Operating income$0.5B($0.18B)
Net income$0.31B($0.28B)
Operating cash flow$0.52B($0.01B)
Capital expenditures($0.06B)($0.03B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

Zacks

Unlocking Q2 Potential of Alnylam (ALNY): Exploring Wall Street Estimates for Key Metrics

RTTNews

Kymera Appoints Rooney As CMO Following Gollob's Retirement

Zacks

CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official QQQ-tracking holdings →

Facts, estimates, and scenario analysis are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Eligibility, consensus, and price data can change. This page is illustrative research, not investment advice.